NT5E and neoplasm: Typically outside of the ICU, CD73 has emerged as an attractive oncologic therapeutic target because the enzyme affects the tumor microenvironment, with tumor CD73 upregulation establishing an anti-inflammatory milieu through the generation of adenosine, promoting tumor growth under hypoxic conditions (Harvey et al., 2020; Roh et al., 2020).